Annals of Oncology 9:63-69, 1998
© 1998 European Society for Medical Oncology
research-article |
G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice
osa1
don1
1Department of Immunology, Institute of Biostructure, Medical School of Warsaw Poland
2Department of Radiation Hematology, WIHiE Poland
3Department of Experimental Hematology, Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology Poland
4Department of Histology and Embryology, Institute of Biostructure, Medical School of Warsaw Poland
Correspondence to: Dr. Marek Jakóbisiak, Department of Immunology, Institute of Biostructure, Medical School of Warsaw, ul. Chaibinskiego 5 02-004 Warsaw Poland E-mail: mjakobis{at}ib.amwaw.edu.pl
Background: IL-12 has been successfully used in experimental tumor therapy. However, administration of this cytokine induces dose-dependent suppression of hematopoiesis that could potentially limit its use in clinical trials. We decided to examine whether the myelosuppressive activity of IL-12 could be corrected by the administration of G-CSF.
Materials and methods: In the initial experiments the influence of IL-12 and/or G-CSF on bone marrow and spleen GM-CFC was evaluated. To examine whether G-CSF could influence the antitumor activity of IL-12 the combination therapy with these agents was carried out starting on day seven following inoculation of melanoma MmB16 cells into the footpads of B6D2F1 mice. To obtain insight into the mechanism of the observed augmented antitumor activity of the combination therapy with IL-12 and G-CSF, the influence of these cytokines on macrophage activity (cytotoxicity and nitric oxide release) was analyzed.
Results: In accord with our expectations, the application of G-CSF partially prevented the suppression of bone marrow myelopoiesis in IL-12-treated mice. Unexpectedly, G-CSF also showed potentiation of antitumor effects of IL-12 in this melanoma model. The augmented antitumor activity of combined IL-12/G-CSF immunotherapy could result from the enhanced stimulation of macrophage NO production and cytotoxicity.
Conclusion: The simultaneous administration of IL-12 and G-CSF partially prevented suppression of bone marrow myelopoiesis in IL-12-treated mice. Moreover, treatment with these cytokines also results in potentiated antitumor effects in a murine melanoma model.
granulocyte colony-stimulating factor, interleukin-12, melanoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Bottoni, P. Bonaccorsi, V. Devirgiliis, V. Panasiti, R. G. Borroni, G. Trasimeni, R. Clerico, and S. Calvieri Complete Remission of Brain Metastases in Three Patients with Stage IV Melanoma Treated with BOLD and G-CSF Jpn. J. Clin. Oncol., September 1, 2005; 35(9): 507 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jalili, M. Makowski, T. Switaj, D. Nowis, G. M. Wilczynski, E. Wilczek, M. Chorazy-Massalska, A. Radzikowska, W. Maslinski, L. Bialy, et al. Effective Photoimmunotherapy of Murine Colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells Clin. Cancer Res., July 1, 2004; 10(13): 4498 - 4508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Makowski, T. Grzela, J. Niderla, M. Lazarczyk, P. Mroz, M. Kopee, M. Legat, K. Strusinska, K. Koziak, D. Nowis, et al. Inhibition of Cyclooxygenase-2 Indirectly Potentiates Antitumor Effects of Photodynamic Therapy in Mice Clin. Cancer Res., November 1, 2003; 9(14): 5417 - 5422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Golab, D. Olszewska, P. Mroz, K. Kozar, R. Kaminski, A. Jalili, and M. Jakobisiak Erythropoietin Restores the Antitumor Effectiveness of Photodynamic Therapy in Mice with Chemotherapy- induced Anemia Clin. Cancer Res., May 1, 2002; 8(5): 1265 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Scheithauer, G. V. Kornek, M. Raderer, H. Ulrich-Pur, W. Fiebiger, C. Gedlicka, B. Schull, S. Brugger, B. Schneeweiss, F. Lang, et al. Randomized Multicenter Phase II Trial of Oxaliplatin Plus Irinotecan Versus Raltitrexed as First-Line Treatment in Advanced Colorectal Cancer J. Clin. Oncol., January 1, 2002; 20(1): 165 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Przepiorka, T. L. Smith, J. Folloder, P. Anderlini, K.-W. Chan, M. Korbling, B. Lichtiger, F. Norfleet, and R. Champlin Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors Blood, June 1, 2001; 97(11): 3405 - 3410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview J. Clin. Oncol., March 1, 2001; 19(5): 1501 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dabrowska, J. Golab, A. Giermasz, M. Marczak, and M. Jakobisiak Re: Macrophage Role in the Anti-Prostate Cancer Response to One Class of Antiangiogenic Agents J Natl Cancer Inst, May 5, 1999; 91(9): 804b - 805b. [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Car, V. M. Eng, J. M. Lipman, and T. D. Anderson The Toxicology of Interleukin-12: A Review Toxicol Pathol, January 1, 1999; 27(1): 58 - 63. [Abstract] [PDF]
|
|
|
|
|
|
J. Golab, R. Zagozdzon, T. Stoklosa, W. Lasek, M. Jakobisiak, Z. Pojda, and E. Machaj Erythropoietin Prevents the Development of Interleukin-12-Induced Anemia and Thrombocytopenia But Does Not Decrease Its Antitumor Activity in Mice Blood, June 1, 1998; 91(11): 4387 - 4388. [Full Text] [PDF]
|
|